Table 4 Self-reported nose-related symptoms and adverse events at baseline (before initiation of IN DAM) and four-week follow-up
n, % | Baseline | Week-4 follow-up |
|---|---|---|
Stuffy nose | 21 (40.4) | 17 (32.7) |
Runny nose | 29 (55.8) | 32 (61.5) |
Reduced or altered sense of smell | 14 (26.9) | 17 (32.7) |
Burning or itchy nose | 7 (13.5) | 5 (9.6) |
Nose pain | 3 (5.8) | 4 (7.7) |
Epistaxis | 3 (5.8) | 4 (7.7) |